Tailored approaches may help alleviate these side effects, support healthy BC, and improve long-term treatment engagement [15, 27]
NICE guidelines recommend specific GLP-1 receptor agonists as part of a comprehensive approach to diabetes management (NG28) and, in specific circumstances, for weight management in individuals with obesity or overweight with comorbidities (TA875 for semaglutide, TA664 for liraglutide)
Characterization of GLP-1 effects on -cell function after meal ingestion in humans
Follow-up will occur over 12 months, with an additional phone call 30 days after treatment discontinuation
Semaglutide induced central c-Fos activation in 10 brain areas, including hindbrain areas directly targeted by semaglutide, and secondary areas without direct GLP-1R interaction, such as the lateral parabrachial nucleus
Metabolism-Clinical and Experimental